{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:52:52Z","timestamp":1772171572930,"version":"3.50.1"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1004040","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T14:47:48Z","timestamp":1435675668000},"page":"e1004040","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection"],"prefix":"10.1371","volume":"11","author":[{"given":"Ruian","family":"Ke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Loverdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangfei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Lloyd-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.3184","article-title":"Global control of hepatitis C: where challenge meets opportunity","volume":"19","author":"DL Thomas","year":"2013","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"ref2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"D Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"TK Scheel","year":"2013","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"ref4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1478-3231.2010.02383.x","article-title":"Future hepatitis C virus treatment: interferon-sparing combinations","volume":"31","author":"E Gane","year":"2011","journal-title":"Liver Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","article-title":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial","volume":"12","author":"S Pol","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"AS Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e1004064","DOI":"10.1371\/journal.ppat.1004064","article-title":"A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity","volume":"10","author":"H Qi","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1073\/pnas.1101515108","article-title":"Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals","volume":"108","author":"M Robinson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"JM Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"RM Ribeiro","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"MH Powdrill","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus\u201415 years on","volume":"85","author":"P Simmonds","year":"2004","journal-title":"J Gen Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1126\/science.1058321","article-title":"The epidemic behavior of the hepatitis C virus","volume":"292","author":"OG Pybus","year":"2001","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1665-2681(19)31000-2","article-title":"Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review","volume":"12","author":"FI Lieveld","year":"2013","journal-title":"Ann Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-155-6-201109200-00003","article-title":"Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study","volume":"155","author":"V Lo Re 3rd","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"C Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-203","article-title":"Factors influencing adherence in Hepatitis-C infected patients: a systematic review","volume":"14","author":"T Mathes","year":"2014","journal-title":"Bmc Infectious Diseases"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2014the arc of a medical triumph","volume":"370","author":"RT Chung","year":"2014","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/cid\/cis227","article-title":"Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV\/AIDS","volume":"54","author":"N Ford","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.1180556","article-title":"Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco","volume":"327","author":"RJ Smith","year":"2010","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1086\/605630","article-title":"Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship","volume":"49","author":"RR Roberts","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"JA DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS","volume":"15","author":"DR Bangsberg","year":"2001","journal-title":"AIDS"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"DL Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.12342","article-title":"Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b\/ribavirin","volume":"38","author":"SC Gordon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12079","article-title":"Adherence to PEG\/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence","volume":"20","author":"DM Evon","year":"2013","journal-title":"J Viral Hepat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2036.2009.04004.x","article-title":"Review article: adherence to medication for chronic hepatitis C\u2014building on the model of human immunodeficiency virus antiretroviral adherence research","volume":"30","author":"JJ Weiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1473-3099(10)70264-4","article-title":"Population biological principles of drug-resistance evolution in infectious diseases","volume":"11","author":"PA zur Wiesch","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Gelman MA, Glenn JS (2010) Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med.","DOI":"10.1016\/j.molmed.2010.10.005"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"B Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"DI Rosenbloom","year":"2012","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1098\/rspb.2000.1079","article-title":"Adherence and drug resistance: predictions for therapy outcome","volume":"267","author":"LM Wahl","year":"2000","journal-title":"Proc Biol Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkn175","article-title":"Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses","volume":"62","author":"V Soriano","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, et al. (2012) Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options. J Hepatol.","DOI":"10.1016\/j.jhep.2012.09.037"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1073\/pnas.97.14.7681","article-title":"Production of resistant HIV mutants during antiretroviral therapy","volume":"97","author":"RM Ribeiro","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/evo.12048","article-title":"Intergenerational phenotypic mixing in viral evolution","volume":"67","author":"C Loverdo","year":"2013","journal-title":"Evolution"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1111\/j.1558-5646.2012.01687.x","article-title":"Influence of viral replication mechanisms on within-host evolutionary dynamics","volume":"66","author":"C Loverdo","year":"2012","journal-title":"Evolution"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.epidem.2012.10.001","article-title":"Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics","volume":"4","author":"HK Alexander","year":"2012","journal-title":"Epidemics"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pec.2005.09.014","article-title":"Assessing and achieving readiness to initiate HIV medication","volume":"62","author":"O Nordqvist","year":"2006","journal-title":"Patient Educ Couns"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, et al. (2014) Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat.","DOI":"10.1111\/jvh.12271"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Y Karino","year":"2013","journal-title":"J Hepatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/jac\/dkt423","article-title":"Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration","volume":"69","author":"R Ke","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"RE Nettles","year":"2011","journal-title":"Hepatology"},{"key":"ref49","unstructured":"Eley T, Pasquinelli C, Wendelburg P, Villegas C, He B, et al. (2010) Safety and Pharmacokinetics of BMS-650032 Following Multiple Ascending Doses for 14 Days in Healthy Subjects. ICAAC. Boston."},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"RA Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"RA Fridell","year":"2011","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Xiao F, Fofana I, Thumann C, Mailly L, Alles R, et al. (2014) Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut.","DOI":"10.1136\/gutjnl-2013-306155"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, et al. (2014) Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int.","DOI":"10.1111\/liv.12692"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration","volume":"53","author":"J Guedj","year":"2011","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"E Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"J Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.293.10.1223","article-title":"Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review","volume":"293","author":"AX Garg","year":"2005","journal-title":"JAMA"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1137\/S0036144598335107","article-title":"Mathematical analysis of HIV-1 dynamics in vivo","volume":"41","author":"AS Perelson","year":"1999","journal-title":"SIAM review"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e1002744","DOI":"10.1371\/journal.pcbi.1002744","article-title":"Evolutionary analysis of human immunodeficiency virus type 1 therapies based on conditionally replicating vectors","volume":"8","author":"R Ke","year":"2012","journal-title":"PLoS Comput Biol"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1004040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:02:03Z","timestamp":1589018523000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1004040"}},"subtitle":[],"editor":[{"given":"Roger Dimitri","family":"Kouyos","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,30]]},"references-count":60,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1004040","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/008466","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,30]]}}}